Integra LifeSciences Reports First Quarter 2026 Financial Results
Integra LifeSciences reported Q1 2026 revenue of $391.9 million, up 2.4% reported and 1.3% organic year-over-year, with adjusted EPS rising to $0.54 from $0.41 in the prior year. The company raised its full-year 2026 adjusted EPS guidance range to $2.40-$2.50, up from the previous $2.30-$2.40, while reaffirming its revenue guidance of $1.662 billion to $1.702 billion.
Key figures
- Eps
- 0.54
- Revenue
- $391.9 million
- Guidance
- FY26 revenue $1.662B-$1.702B, Adj EPS raised to $2.40-$2.50 from $2.30-$2.40
- Revenue Yoy
- 2.4%
- Net Debt
- $1.6 billion
- Leverage Ratio
- 4.1x
- Adjusted EBITDA
- $76.2 million
- Adjusted EBITDAMargin
- 19.4%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.